SharpyApitegromab (Isembyld): The Muscle Drug Tested With Zepbound
Apitegromab is a myostatin-blocking antibody from Scholar Rock. The FDA approved it as Isembyld (apitegromab-mstn) on September 11, 2026, but only for spinal muscular atrophy (SMA). In the Phase 2 EMBRAZE trial, people on tirzepatide plus apitegromab lost about 1.9 kg (4.2 lb) less lean mass over 24 weeks than people on tirzepatide alone, with similar weight loss. It is not approved for weight loss, so protein and strength training are still your best muscle tools, and Sharpy helps you track both.
What is apitegromab, and can it stop the muscle loss that comes with Zepbound, Mounjaro or Wegovy? Apitegromab is an antibody from Scholar Rock that blocks myostatin, the body's brake on muscle growth. The FDA approved it on September 11, 2026, under the brand name Isembyld (apitegromab-mstn), but only for spinal muscular atrophy (SMA). In a 24-week trial called EMBRAZE, adding it to tirzepatide cut lean mass loss roughly in half. It is not approved for weight loss.
Muscle loss on GLP-1 drugs is back in the news this week. On October 24, 2026, outlets covered a Northwestern University mouse study in PNAS on a gene-silencing therapy given with semaglutide. That work is still in mice. Apitegromab is much further along, and it is the only drug in this space with an FDA approval for anything. Here is what it does, what the trial found and what it means for you.
What is apitegromab and how does it work?
When you lose weight, some of it is lean mass: muscle, organs, water and bone. In EMBRAZE, about 30% of the weight people lost on tirzepatide alone was lean mass.
Apitegromab is a fully human monoclonal antibody. It grabs myostatin before it becomes active. Scholar Rock says it binds the "pro" and "latent" forms of myostatin, which mostly sit in skeletal muscle. With myostatin switched off, muscle gets a weaker "stop growing" signal.
That is the same idea behind Regeneron's trevogrumab. The difference is that apitegromab has already passed a Phase 3 trial and earned an FDA approval, in a different disease.
Apitegromab FDA approval: Isembyld for SMA
| Fact | Detail |
|---|---|
| Brand name | Isembyld (apitegromab-mstn) |
| Maker | Scholar Rock (Nasdaq: SRRK) |
| FDA approval | September 11, 2026 |
| Approved for | SMA in adults and children 2+ already on an SMN2-targeted treatment |
| Dose | 10 mg/kg by IV infusion, given by a healthcare provider |
| Key trial | Phase 3 SAPPHIRE: 2.2-point gain on a motor function scale vs placebo at one year |
| Main warning | Fractures: 9% on Isembyld vs 2% on placebo in SAPPHIRE |
| Weight loss use | Not approved |
The road to approval was bumpy. The FDA turned down the first application in September 2025 because of problems at a fill-finish plant run by Catalent Indiana, which Novo Nordisk now owns. Scholar Rock says efficacy and safety were not the issue. It refiled with a second plant and won approval about three weeks before its September 30, 2026 deadline.
In Europe, the EMA validated Scholar Rock's application for SMA in March 2025. We found no EMA decision yet.
Apitegromab and tirzepatide: EMBRAZE trial results
EMBRAZE was a Phase 2, double-blind trial in adults with a BMI of 30 or more, or 27 or more with a weight-related health problem. Everyone took tirzepatide, the drug in Zepbound and Mounjaro. Half also got apitegromab 10 mg/kg and half got placebo, for 24 weeks. Body makeup was measured with DEXA scans. Scholar Rock released the topline numbers on June 18, 2025, and the full paper appeared in Nature Medicine on June 8, 2026.
| At 24 weeks | Tirzepatide + apitegromab (n=43) | Tirzepatide + placebo (n=44) |
|---|---|---|
| Lean mass change | -1.6 kg (-3.4 lb) | -3.5 kg (-7.6 lb) |
| Fat mass change | -8.5 kg (-18.8 lb) | -8.0 kg (-17.7 lb) |
| Body weight change | -11.2 kg (-12.3%) | -12.5 kg (-13.4%) |
| Share of weight lost that was lean mass | 14.6% | 30.2% |
| Share of weight lost that was fat | 85.3% | 69.5% |
What this means in plain words:
- About 1.9 kg (4.2 lb) more lean mass was kept. Scholar Rock calls this "54.9% preservation." That is a relative number. The real-world gap is the 1.9 kg.
- Fat loss was about the same. People lost slightly less total weight with apitegromab, because they kept more muscle.
- Strength did not improve on paper. The published trial did not show better physical function, strength or heart and metabolic markers at 24 weeks. The authors said bigger, longer trials are needed, especially in older adults.
- Side effects were similar. Reports of the Nature Medicine paper put adverse events at 76% with apitegromab and 71% with placebo, mostly the usual tirzepatide stomach effects. Scholar Rock funded the trial.
Apitegromab side effects
Most safety data comes from SMA. Scholar Rock says more than 500 people have received apitegromab across its studies, some for over seven years. From the Isembyld release:
- Common: upper respiratory infections, vomiting, cough, viral infections, headache, stomach flu, sore throat and allergic-type reactions.
- Fractures: 9% versus 2% on placebo. Fractures can happen without a fall. Tell your doctor about low bone density or past fractures.
- Pregnancy and breastfeeding: it is not known if it harms an unborn baby or passes into breast milk. Ask a doctor.
The fracture signal matters for GLP-1 users. Fast weight loss can also lower bone density, so this would need careful study in people without SMA.
Apitegromab price, cost and how to get it
Scholar Rock did not list a price in its approval announcement. Coverage and financial help for SMA patients run through its Scholar Rock Supports program.
For weight loss, there is no approved path. Scholar Rock's latest quarterly report says the company is focused on rare muscle diseases and is "seeking partners" to study myostatin blockers with GLP-1 drugs. Its shot-under-the-skin antibody, SRK-439, is in a Phase 1 study in healthy volunteers.
Be careful with "apitegromab for sale" listings. The real drug is a large antibody made in sterile plants and given by IV. Vials or "peptides" sold online are not Isembyld. See our guide to compounded GLP-1s for why unregulated injectables carry real risk.
Apitegromab vs other muscle-saving drugs
| Drug | Company | Blocks | Tested with | Status |
|---|---|---|---|---|
| Apitegromab | Scholar Rock | Myostatin (pro and latent forms) | Tirzepatide | Approved for SMA only |
| Trevogrumab | Regeneron | Myostatin | Semaglutide | Phase 2 |
| Garetosmab | Regeneron | Activin A | Semaglutide + trevogrumab | Phase 2 |
| Bimagrumab | Eli Lilly | Activin type II receptors | Semaglutide, tirzepatide | Phase 2 |
None of these drugs has been tested head to head with another, and none is approved for weight loss.
What you can do about muscle loss today
The tools that work right now are cheap and safe. Eat enough protein, often 0.7 to 1.0 grams per pound of goal weight, split across meals, as our protein target guide explains. Lift or do resistance work two to three times a week. Our beginner strength program needs no gym.
This is where Sharpy fits. It gives you one daily protein target, one 20-minute strength workout and a Shape Score, so you can see whether you are losing fat and keeping muscle. If you are over 50, read our sarcopenia guide, since muscle is harder to rebuild with age.
The bottom line
Apitegromab is real, approved and promising, but only for SMA. Its weight-loss data is one 24-week trial in 87 people that saved muscle on scans without proving strength gains. Until bigger trials report, keep muscle the old way. Sharpy can help you track protein and workouts every day, and your prescriber can help you decide what is right for you.
Sources
- Scholar Rock: FDA approval of ISEMBYLD (Sep 11, 2026), SEC 8-K exhibit
- Scholar Rock: EMBRAZE Phase 2 topline results (Jun 18, 2025), SEC 8-K exhibit
- Pratley et al., Nature Medicine (2026): Apitegromab for lean mass preservation during tirzepatide-induced weight loss
- Scholar Rock Form 10-Q, quarter ended June 30, 2026
- STAT: FDA approves Scholar Rock's Isembyld (Sep 11, 2026)
- Earth.com: New therapy may prevent muscle loss from weight-loss drugs (Oct 24, 2026)
Questions people ask
What is apitegromab?
Apitegromab is a fully human monoclonal antibody made by Scholar Rock, a company in Cambridge, Massachusetts. It binds to the inactive forms of myostatin (promyostatin and latent myostatin) and stops myostatin from switching on. Myostatin is a natural protein that limits muscle growth, so blocking it helps muscle hold on.
Is apitegromab FDA approved?
Yes, but only for spinal muscular atrophy. The FDA approved it as Isembyld (apitegromab-mstn) on September 11, 2026, for adults and children 2 years and older with SMA who already take an SMN2-targeted treatment. It is not approved for obesity, weight loss or muscle loss from GLP-1 drugs.
Does apitegromab work with tirzepatide?
In the Phase 2 EMBRAZE trial, adults with obesity or overweight took tirzepatide plus either apitegromab 10 mg/kg or placebo for 24 weeks. Lean mass made up 14.6% of the weight lost with apitegromab and 30.2% with placebo. Total weight loss was similar: 12.3% versus 13.4%. The trial did not show better strength or physical function.
How is apitegromab administered?
Apitegromab is given by a healthcare provider as an IV infusion into a vein. The approved SMA dose is 10 mg/kg, based on body weight. In EMBRAZE it was given as an infusion every four weeks. It is not a pen or a pill. Scholar Rock is testing a separate shot-under-the-skin antibody called SRK-439 in an early safety study.
What are the side effects of apitegromab?
In the SMA trial, the most common side effects were upper respiratory infections, vomiting, cough, viral infections, headache, stomach flu, sore throat and allergic-type reactions. Fractures happened in 9% of people on apitegromab and 2% on placebo, and the label warns about fracture risk. In EMBRAZE, side effects were similar between groups and were mostly the usual tirzepatide effects.
Can I get apitegromab for weight loss?
Not as an approved use. Isembyld is approved only for SMA, and its long-term effects in people using GLP-1 drugs have not been studied. Scholar Rock says it is looking for partners to study the weight-loss use further. Products sold online as apitegromab or "apitegromab peptide" are not the approved medicine, and their contents are unknown. Talk to your prescriber about muscle loss instead.